1. Home
  2. PODD vs GPN Comparison

PODD vs GPN Comparison

Compare PODD & GPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PODD
  • GPN
  • Stock Information
  • Founded
  • PODD 2000
  • GPN 1967
  • Country
  • PODD United States
  • GPN United States
  • Employees
  • PODD N/A
  • GPN N/A
  • Industry
  • PODD Medical/Dental Instruments
  • GPN Business Services
  • Sector
  • PODD Health Care
  • GPN Consumer Discretionary
  • Exchange
  • PODD Nasdaq
  • GPN Nasdaq
  • Market Cap
  • PODD 22.1B
  • GPN 20.6B
  • IPO Year
  • PODD 2007
  • GPN 2001
  • Fundamental
  • Price
  • PODD $321.81
  • GPN $76.64
  • Analyst Decision
  • PODD Strong Buy
  • GPN Buy
  • Analyst Count
  • PODD 18
  • GPN 22
  • Target Price
  • PODD $341.00
  • GPN $103.15
  • AVG Volume (30 Days)
  • PODD 525.5K
  • GPN 2.1M
  • Earning Date
  • PODD 11-06-2025
  • GPN 11-04-2025
  • Dividend Yield
  • PODD N/A
  • GPN 1.31%
  • EPS Growth
  • PODD N/A
  • GPN 34.30
  • EPS
  • PODD 3.45
  • GPN 7.12
  • Revenue
  • PODD $2,521,800,000.00
  • GPN $10,076,185,000.00
  • Revenue This Year
  • PODD $29.32
  • GPN N/A
  • Revenue Next Year
  • PODD $18.37
  • GPN $5.66
  • P/E Ratio
  • PODD $93.81
  • GPN $10.73
  • Revenue Growth
  • PODD 27.11
  • GPN 22.33
  • 52 Week Low
  • PODD $230.05
  • GPN $65.93
  • 52 Week High
  • PODD $353.50
  • GPN $120.00
  • Technical
  • Relative Strength Index (RSI)
  • PODD 51.69
  • GPN 34.67
  • Support Level
  • PODD $309.27
  • GPN $74.71
  • Resistance Level
  • PODD $322.86
  • GPN $80.99
  • Average True Range (ATR)
  • PODD 9.90
  • GPN 2.38
  • MACD
  • PODD -0.11
  • GPN -0.85
  • Stochastic Oscillator
  • PODD 70.17
  • GPN 13.50

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

About GPN Global Payments Inc.

Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.

Share on Social Networks: